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Hypothyroidism: General 
Background  
1. Definitions  
o Hypothyroidism:  
 Clinical state marked by diminished production of thyroid hormone  
o Subclinical hypothyroidism  
 Slightly elevated TSH (5-10 mU/L) w/ nml free T4 & T3; symptomatic or 
mild Sx 
2. Physiology  
o Hypothalamus secretes TRH stimulates antr pituitary 
o Pituitary secretes TRH stimulates antr pituitary 
o Thyroid hormones influence diverse metabolic processes 
3. Guidelines sn of Clinical Endocrinologists' Medical Guidelines for Clinical Practice for 
the Evaluation and Treatment of Hyper- and Hypothyroidism  
o http://www.aace.com/pub/guidelines 
4. See also subclinical hypothyroidism 
Pathophysiology 
1. Primary hypothyroidism  
o 95% of cases primary process in thyroid  
o High TSH, low T4 & T3  
o Pathology  
 Hashimoto's thyroiditis (most common cause)  
 Also known as chronic lymphocytic thyroiditis  
 Autoimmune process  
 Antibodies to thyroid peroxidase in 90% of pts  
 Antibodies to thyroglobulin in 80% of pts  
o Iatrogenic (second most common cause)  
 Radioactive iodine Tx  
 Antithyroid drugs (propylthiouracil [PTU], methimazole)  
 Surgical removal of gland  
 Other meds  
 Lithium  
 Amiodarone  
 Interferon  
 Radiation of head & neck  
o Infiltrative dz of thyroid (less common)  
 Sarcoid  
 Amyloid  
 Lymphoma  
o Hypothyroid phase of thyroiditis  
 Acute  
 Subacute  
 Silent  
2. Secondary hypothyroidism  
o 5% of cases  
o Pituitary or hypothalamic process  
 Neoplasm  
 Pituitary necrosis  
 Congenital hypopituitarism  
o Low TSH, low T4 & T3  
3. Myxedema  
o Hypothyroid state w/ hard edema of subcutaneous tissues and more severe Sx of 
hypothyroidism 
4. Myxedema coma  
o Medical emergency precipitated by stress / trauma  
5. Incidence & prevalence  
o 0.3-0.4% of adults  
 4% subclinical hypothyroidism (TSH > 4.5milliunits/L; normal T4)  
o 0.5% of pregnancies  
o 2-3% of older women affected  
6. Risk factors  
o Age: prevalence incr w/ age  
o Gender: women > men  
o Postpartum state  
o Hx of radiation therapy to head or neck  
o HIV infection  
7. Comorbid autoimmune disorders  
o Addison's dz  
o Diabetes mellitus  
o Pernicious anemia  
o Rheumatoid arthritis  
o Vitiligo  
o SLE  
8. Assoc conditions  
o Mitral valve prolapse 
o Hypogonadism 
o Hyperlipidemia 
9. Morbidity / mortality  
o Myxedema coma  
 Hypothermia 
 Hypoglycemia 
 Hypoventilation 
 Stuporous state 
 50-75% mortality 
o Cardiac complications  
 Heart failure 
 Pericardial effusion 
 Bradycardia 
 Hypertension 
Diagnostics 
1. History  
o Symptoms  
 Fatigue, lethargy 
 Apathy, decr mood 
 Dry skin 
 Cold intolerance 
 Hair loss 
 Impaired memory 
 Constipation 
 Wt gain 
 Muscle weakness, cramps 
 Dyspnea 
 Hoarseness 
 Menstrual irregularities  
 Menorrhagia 
 DUB 
 Pretibial or facial edema 
o Other findings  
 Hyperlipidemia  
 Hyponatremia  
2. Physical exam  
o HEENT  
 Puffy face/eyelids 
o Neck  
 Goiter, nodules 
o Cardiac  
 Bradycardia 
 Cardiomegaly 
 Pericardial effusion 
o Skin  
 Dry 
 Coarse hair 
 Pretibial non-pitting edema 
o Reflexes  
 Delayed relaxation of DTRs 
3. Diagnostic testing  
o Labs  
 TSH  
 Elevated 
 Preferred test for initial evaluation of primary hypothyroidism  
 If abnormal, check free T4  
 Free T4  
 Low 
 T3  
 Check T3 if TSH undetectable and free T4 nml  
 T3 often nml even if pt severely hypothyroid  
o Addl labs (optional)  
 TPOAb, thyroglobulin, and TRAb  
 Three principal thyroid antibodies 
 Can be pos in variety of autoimmune thyroid disorders  
o Imaging  
 No U/S or radioactive iodine uptake (RAIU) test indicated unless nodule 
present  
 If nodule present, consider U/S or RAIU, possible FNA 
Differential Diagnosis 
1. Many common disorders have overlapping Sx w/ hypothyroidism  
o Anemia 
o Alzheimer's dz 
o Chronic fatigue syndrome 
o Rheumatologic dz 
o Depression 
2. TSH assay will establish Dx 
Therapeutics 
See also subclinical hypothyroidism, severe hypothyroidism (myxedema) 
1. Levothyroxine  
o Full replacement dose for adult: 1.6 mcg/kg/d  
o Usual starting dose for adult < 50 yo: 75 mcg/d  
o Use lower dose if elderly or heart dz  
 Start w/ 12.5-50 mcg/d  
o Use same brand throughout Tx  
o Drug interactions  
 Decr absorption of levothyroxine if on  
 Cholestyramine 
 Iron 
 Sucralfate 
 Calcium 
 Antacids w/ aluminum hydroxide 
 Caffeine 
 Fiber supplement 
 Incr metabolism of levothyroxine if on  
 Rifampin 
 Phenobarbital 
 Carbamazepine 
 Warfarin 
 Oral hypoglycemic agents 
 Phenytoin 
 Estrogen 
Special Populations 
1. Elderly  
o Full replacement dose of levothyroxine: 1 mcg/kg/d  
o Initial Tx w/ 25-50 mcg/d, incr gradually  
2. Pregnancy  
o Must treat preg women w/ hypothyroidism to prevent maternal & fetal 
complications  
o Check TSH every 6 wk during pregnancy  
o Adjust levothyroxine prn (dose requirement may incr)  
 30% incr suggested at confirmation of pregnancy  
o Return to prepregnancy dose postpartum  
3. Children  
o May require up to 4 mcg/kg/d of levothyroxine  
o Refer to endocrinologist  
Follow-up 
1. Return to office in 6-8 wk to check TSH / adjust levothyroxine dose  
2. Once TSH nml, annual levels  
3. More freq monitoring if  
o Pregnant  
o Using estrogen  
o Sig wt loss/gain  
o Return of clinical Sx  
4. If TSH not normalizing, consider noncompliance  
5. Refer to specialist  
o Nodule  
o Goiter  
o Age < 18 yo  
o Pregnant  
o Not responding to Tx  
o Cardiac pt  
o Endocrine disorder  
6. Admit to hospital if myxedema coma  
o Consider IV thyroid hormone replacement  
Prognosis 
1. Life-long thyroid hormone replacement typically required 
2. Subclinical hypothyroidism - 40% progression to hypothyroidism 
Prevention / Screening  
1. Not enough evidence for or against screening  
2. Newborns routinely screened  
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